Warner Chilcott Reports Operating Results for the Quarter and Year Ended Decembe... ( Growth of promoted product revenue an...)

Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008

Date:2/27/2009

Growth of promoted product revenue and reduced expenses continue to drive solid cash net income growth

HAMILTON, Bermuda, Feb. 27 /PRNewswire-FirstCall/ -- Warner Chilcott Limited (Nasdaq: WCRX) today announced its results for the quarter and year ended December 31, 2008. Revenue in the quarter ended December 31, 2008 totaled $242.5 million, an increase of 6.5%, over the prior year quarter. Revenue for the year ended December 31, 2008 totaled $938.1 million, an increase of 4.3%, over the prior year. The primary drivers of the increase in revenue for both periods were the net sales of our promoted products DORYX, TACLONEX, LOESTRIN 24 FE and FEMCON FE, which together contributed $34.2 million and $130.9 million of revenue growth for the quarter and year ended December 31, 2008, respectively, compared to the prior year periods. The growth delivered by these products was offset primarily by significant declines in SARAFEM and ESTROSTEP FE net sales due primarily to generic competition and declines in DOVONEX net sales.

The Company reported a net (loss) of $(115.7) million, or $(0.46) per diluted share, in the quarter ended December 31, 2008, compared with net income of $19.7 million, or $0.08 per diluted share, in the prior year quarter. The quarter ended December 31, 2008 included a non-cash impairment charge related to the Company's OVCON / FEMCON FE intangible asset of $163.3 million ($0.64 per diluted share, net of tax). Excluding this impairment charge, net income was $44.4 million in the quarter ended December 31, 2008. Cash net income ("CNI") in the quarter ended December 31, 2008 was $100.5 million, an increase of $26.6 million, compared to $73.9 million in the prior year quarter. Reported net (loss) was $(8.4) million, or $(0.03) per diluted share, in the year ended December 31, 2008.

References in th
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine news :

1. Warner Chilcott Announces 2009 Financial Guidance
2. Warner Chilcott Announces 2009 Financial Guidance Conference Call
3. Warner Chilcott Files New Lawsuit for Infringement of DORYX(R) Patent
4. Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
5. Warner Chilcott to Present at the 27th Annual JP Morgan Healthcare Conference
6. Warner Chilcott and Dong-A Sign U.S. License Agreement For Erectile Dysfunction Treatment
7. Warner Chilcott to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
8. Warner Chilcott Announces Receipt of Paragraph IV Certification Notices
9. Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance
10. Warner Chilcott Announces Earnings Release Date and Conference Call for Third Quarter 2008 Financial Results
11. House Passes Historic Bill to Protect Kids From Tobacco; Senators Webb & Warner Should Cosponsor Legislation

Post Your Comments:

(Date:4/17/2014)... NEW YORK, NY (April 16, 2014) The cause ... but a new study proposes that neurons may be ... own immune system, similar to the way autoimmune diseases ... attack the body,s cells. The study was published April ... is a new, and likely controversial, idea in Parkinson,s ...

(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit ... issues, published a comprehensive review today examining the current ... virus. The review calls for improved global surveillance strategies ... the recent outbreak of Ebola in West Africa that ... countries of Guinea and Liberia. According to the ...

(Date:4/17/2014)... Population Council scientists and their partners have found that ... prevent the transmission of multiple sexually transmitted infections (STIs) ... herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV). ... the gel is effective against multiple strains of HIV, ... against all three viruses of at least eight hours ...

(Date:4/17/2014)... world is less than 40 years away from a ... and governments, according to a top scientist at the ... in human history, food production will be limited on ... and energy," said Dr. Fred Davies, senior science advisor ... could become as politically destabilizing by 2050 as energy ...

(Date:4/17/2014)... Patrick Johnston, whose work has transformed cancer care in ... the European Academy of Cancer Sciences., The Academy, which ... of highly distinguished oncologists and cancer researchers which aims ... in Europe. , Professor Johnston, whose leadership has seen ... bottom of the UK league table to near the ...

Breaking Medicine News(10 mins):Health News:Is Parkinson's an autoimmune disease? 2 Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2 Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3 Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2 Health News:Food shortages could be most critical world issue by mid-century 2

[0] Is Parkinson's an autoimmune disease?[0] Re-emergence of Ebola focuses need for global surveillance strategies [0] Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum [0] Food shortages could be most critical world issue by mid-century [0] Queen's University Vice-Chancellor receives top European award

... marketed as Revatio, study finds , TUESDAY, May 18 ... that causes progressive scarring of the lung tissue might ... Viagra, a new study finds. , The disease, called ... thick and stiff, reducing the ability to breathe. There,s ...

... life, study finds , TUESDAY, May 18 (HealthDay News) -- ... hurt feelings. Now, new research shows that a warm, caring ... growing up poor -- protection that can last well into ... with a higher risk for heart disease and other mental ...

... of the University of Helsinki, and Oncos Therapeutics, the ... next generation oncolytic viruses, published initial results from their ... The therapy program is based on scientific research at ... for ongoing clinical development. The results demonstrate ...

... the care they provide can vary widely depending upon the ... to a new RAND Corporation study. Researchers say the ... cost profiles that are being created by insurance companies in ... study provides more evidence that efforts to create physician cost ...

... will allow researchers to conduct larger, more effective studies ... in the United States. With a ... and Reinvestment Act of 2009, Cincinnati Children,s Hospital Medical ... (REGID). The first of its kind registry ...

... ... ever before. Get the facts on cancer and ways to prevent it from the Pulitzer ... ... the nation in the prevention and treatment of cancer. Truecancerfacts.com was written by Pulitzer Prize ...

Cached Medicine News:Health News:Viagra May Aid Those With Lung Fibrosis 2 Health News:Viagra May Aid Those With Lung Fibrosis 3 Health News:A Mother's Love Overcomes Poverty's Effect on Health 2 Health News:A Mother's Love Overcomes Poverty's Effect on Health 3 Health News:Oncolytic viruses mediating anti-tumor immunity in human cancer patients 2 Health News:Results of physician cost profiling can vary widely, study finds 2 Health News:National registry to track eosinophilic disorders 2 Health News:What Doctors Won't Tell Their Patients About Cancer 2

Viagra May Aid Those With Lung Fibrosis A Mother's Love Overcomes Poverty's Effect on Health Oncolytic viruses mediating anti-tumor immunity in human cancer patients Results of physician cost profiling can vary widely, study finds National registry to track eosinophilic disorders What Doctors Won't Tell Their Patients About Cancer

(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...

(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...

(Date:1/14/2014)... Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a ... it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... terms of the acquisition were not disclosed. ... providing a wide range of sleep, mobility, and respiratory products ...

[0] Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users [0] HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues [0] Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment

... 7 Novartis Pharmaceuticals Corporation today announced the ... 0.5 mg daily, a first-line oral treatment for ... by the US Food and Drug Administration (FDA) ... with MS and healthcare professionals seeking information about ...

... Privigen®, the first and only 10% ... is effective and well tolerated in patients with ... presented today at the XIVth Meeting of the ... Privigen offers significant protection against infection. ...

Cached Medicine Technology:Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya 2 Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya 3 Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya 4 Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya 5 Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya 6 Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya 7 Privigen® Demonstrates Efficacy and Tolerability Among Patients With Various Immunodeficiencies, Data Show 2 Privigen® Demonstrates Efficacy and Tolerability Among Patients With Various Immunodeficiencies, Data Show 3

Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya Privigen® Demonstrates Efficacy and Tolerability Among Patients With Various Immunodeficiencies, Data Show

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

Medicine Products:

Cobalamin CMV Antibody, IgM CMV Ab, IgG Quantitative Clozapine